Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
(R)-Roscovitine (CYC202) is often referred to as a "selective inhibitor of cyclin-dependent kinases." Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis studies, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, viral infections, and glomerulonephritis. We have investigated the selectivity of (R)-roscovitine using three different methods: 1) testing on a wide panel of purified kinases that, along with previously published data, now reaches 151 kinases; 2) identifying roscovitine-binding proteins from various tissue and cell types following their affinity chromatography purification on immobilized roscovitine; 3) investigating the effects of roscovitine on cells deprived of one of its targets, CDK2. Altogether, the results show that (R)-roscovitine is rather selective for CDKs, in fact most kinases are not affected. However, it binds an unexpected, non-protein kinase target, pyridoxal kinase, the enzyme responsible for phosphorylation and activation of vitamin B6. These results could help in interpreting the cellular actions of (R)-roscovitine but also in guiding the synthesis of more selective roscovitine analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003) · Cell Proliferation · doi:10.1046/j.1365-2184.2003.00266.x · Cited by 1,773
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Self-citationProtein Kinase Inhibitors: Insights into Drug Design from Structure
Noble, M. E. M., Endicott, J. A., & Johnson, L. N. (2004) · Science · doi:10.1126/science.1095920 · Cited by 1,198
Pyridoxal Phosphate Enzymes: Mechanistic, Structural, and Evolutionary Considerations
Eliot, A. C., & Kirsch, J. F. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.074021 · Cited by 950
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Self-citationThe selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Target identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Target profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
Rossi, A. G., Sawatzky, D. A., Walker, A., Ward, C., Sheldrake, T. A., Riley, N. A., Caldicott, A., Martinez-Losa, M., Walker, T. R., Duffin, R., et al. (2006) · Nature Medicine · doi:10.1038/nm1468 · Cited by 509
Exploring the specificity of the PI3K family inhibitor LY294002
Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462
Target deconvolution strategies in drug discovery
Terstappen, G. C., Schlüpen, C., Raggiaschi, R., & Gaviraghi, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2410 · Cited by 429
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
The emerging role of mass spectrometry-based proteomics in drug discovery
Meissner, F., Geddes-McAlister, J., Mann, M., & Bantscheff, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00409-3 · Cited by 341
Chk1 promotes replication fork progression by controlling replication initiation
Petermann, E., Woodcock, M., & Helleday, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005031107 · Cited by 308
Identifying the proteins to which small-molecule probes and drugs bind in cells
Ong, S.-E., Schenone, M., Margolin, A. A., Li, X., Do, K., Doud, M. K., Mani, D. R., Kuai, L., Wang, X., Wood, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900191106 · Cited by 304
An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ
Banks, A. S., McAllister, F. E., Camporez, J. P. G., Zushin, P.-J. H., Jurczak, M. J., Laznik-Bogoslavski, D., Shulman, G. I., Gygi, S. P., & Spiegelman, B. M. (2015) · Nature · doi:10.1038/nature13887 · Cited by 297
Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine
Bukanov, N. O., Smith, L. A., Klinger, K. W., Ledbetter, S. R., & Ibraghimov-Beskrovnaya, O. (2006) · Nature · doi:10.1038/nature05348 · Cited by 276
Vitamin B6 salvage enzymes: Mechanism, structure and regulation
di Salvo, M. L., Contestabile, R., & Safo, M. K. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.12.006 · Cited by 263
Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
Atkinson, N. J., Witteveldt, J., Evans, D. J., & Simmonds, P. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku075 · Cited by 192
“This is despite having no identified inhibitory activity against PKR and being largely specific for the cell cycle regulation proteins, CDK1, CDK2, CDK5, CDK7 and CDK9 (46,47).”
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Self-citationRoscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
Self-citationCircadian disruption in experimental cancer processes
Filipski, E., & Lévi, F. (2009) · Integrative Cancer Therapies · doi:10.1177/1534735409352085 · Cited by 125
Residual Cdk1/2 activity after DNA damage promotes senescence
Müllers, E., Silva Cascales, H., Burdova, K., Macurek, L., & Lindqvist, A. (2017) · Aging Cell · doi:10.1111/acel.12588 · Cited by 56
Corbel, C., Wang, Q., Bousserouel, H., Hamdi, A., Zhang, B., Lozach, O., Ferandin, Y., Tan, V. B. C., Guéritte, F., Colas, P., et al. (2011) · Biotechnology Journal · doi:10.1002/biot.201100138 · Cited by 35
Self-citation
Metadata
- Authors
- Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., Liang, D.-C., Galons, H., Dierick, J.-F., Pinna, L. A., Meggio, F., Totzke, F., Schächtele, C., Lerman, A. S., Carnero, A., Wan, Y., Gray, N., & Meijer, L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 280
- Issue
- 35
- Pages
- 31208-31219
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2115346062
- Cited by
- 356
- References
- 52
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.